TACR1 and colonic neoplasm: This finding expands our understanding of targeting the NK‐1R‐mediated GPCR signaling in human colon cancer cells and may be applied as a predictive biomarker for evaluation of the efficacy of NK‐1R antagonists in clinical settings.